By vgreene, 30 October, 2020 Multicenter RCT 242 hospitalized pts median age 59 8y w moderate dz received TCZ 8 mg kg x1 SOC n 161 or placebo n 81 concomitant RDV HCQ CS use permitted
By vgreene, 30 October, 2020 Study considerations small sample size SOC evolved during trial significant baseline differences despite randomization
By vgreene, 30 October, 2020 TCZ had lower risk of death vs no TCZ HR 0 71 95 CI 0 56 0 92 30 day mortality TCZ 27 5 vs 37 1 risk difference 9 6 95 CI 3 1 16
By vgreene, 30 October, 2020 Multicenter cohort study 3 924 hospitalized pts median age 62y received TCZ w in 2 days of ICU admission n 433 vs no TCZ TCZ pts were younger w higher prevalence of hypoxemia on ICU admission and more likely to receive CS
By vgreene, 30 October, 2020 Study considerations non randomized inverse probability weighting significant imbalances btwn groups number of TCZ doses not recorded CS duration not recorded missing data for some key variables
By vgreene, 30 October, 2020 KEY FINDINGS early TCZ use assoc w lower in hospital mortality in critically ill
By vgreene, 30 October, 2020 Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID 19
